Nyxoah S.A. (NYXH), a medical technology company, will release financial results for the fourth quarter and financial year 2023 on March 5, 2024, after market close.
The company's flagship product is Genio system, a CE-Mark validated, patient-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea. The Genio system has been available in Europe for treating Obstructive Sleep Apnea since 2019. It was granted CE mark approval in Europe for expanded use in treating patients with a Complete Concentric Collapse in October 2021.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com